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Abstract
Although a recent clinical trial (BEST TRIP) demonstrated no improvement in outcomes with invasive intracranial
pressure (ICP) monitoring (ICPM) following severe traumatic brain injury (TBI), its generalizability has been called into
question. In several global settings ICPM is not the standard of care and is used at the discretion of the attending
neurosurgeon. Our objective was to determine the impact of ICPM on mortality and 6-month functional outcomes
following severe TBI. The setting was a referral trauma center with 36 intensive care unit (ICU) beds and 300–600 TBI
admissions per year. During a 2-year period data were prospectively entered into a severe TBI registry. Patients with
severe TBI aged >12 years meeting Brain Trauma Foundation (BTF) criteria for ICPM were included in the study.
Outcomes of interest were in-hospital mortality and poor 6-month functional outcome defined as Glasgow Outcome Scale
(GOS) score of 3 or lower. A propensity score based analysis incorporating known predictors of outcome in TBI was
utilized to examine the impact of ICPM on outcomes. Of 1345 patients meeting study criteria 497 (37%) underwent ICPM.
In-hospital mortality was 35% (471/1345). Of 454 patients for whom 6-month outcome was available, 161 (35%) suffered
a poor functional outcome. Following propensity score analysis ICPM use was associated with an 8% ( p = 0.002) decrease
in mortality but no significant effect ( p = 0.2) on functional outcome. The use of ICPM following severe TBI was
associated with decreased in-hospital mortality. Further clinical trials of ICPM in TBI may be warranted.
Key words: developing countries; Glasgow Outcome Scale; intracranial pressure; traumatic brain injury
Introduction
Worldwide, severe traumatic brain injury (TBI) is themost common cause of death and disability following injury,
with motor vehicle-related injuries being the most common cause of
TBI.1–3 The magnitude of the problem is particularly large in low-
and middle-income nations, where more than 80% of the world’s
population lives.4 TBI is the leading cause of disability in people
under 40, resulting in severe disability for 150–200 people per mil-
lion annually.5–8 Monitoring and control of intracranial pressure
(ICP) in patients with severe TBI, defined by a Glasgow Coma Scale
(GCS) score £8, is an important part of Brain Trauma Foundation
(BTF) guidelines, with the BTF recommending the use of invasive
ICP monitoring (ICPM) in appropriate candidates with a goal ICP of
<20–25 mm Hg.9 Adherence to guidelines related to ICPM and
management may have a significant impact on outcomes, with one
study demonstrating an association between the appropriate use of
ICPM and a decrease in mortality in New York State.10,11
The use of ICPM is associated with significant expense, resource
utilization, and some risk, however, with the associated costs being
particularly problematic in resource-constrained environments. In
the absence of definitive evidence of benefit from clinical trials, the
use of ICPM is therefore not typically considered the standard of
care in many lower-income nations. Centers dealing with large
volumes of TBI in these regions use a variety of alternative strat-
egies to assess and manage ICP. Frequent clinical examinations
and computed tomography (CT) imaging are sometimes used
as surrogates for the assessment of ICP. A recent multi-center
randomized clinical trial in South America (the BEST TRIP trial)
demonstrated no benefit to the use of ICPM over a management
protocol based on clinical monitoring and serial CT imaging.12 The
generalizability of the study’s findings have been called into
question, particularly in view of the possible benefits in outcome
demonstrated by the previously mentioned studies in the United
States.10,11 It is possible that differences in therapeutic regimens
used in the two arms (more hypertonic saline and hyperventilation
in the ICPM arm and more barbiturate usage in the clinical/imaging
arm), reflective of regional practice, may have had an impact on
outcome in the BEST TRIP trial. It is also possible that strict
adherence to the clinical monitoring and management protocol
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used in the control arm, in the setting of a clinical trial, may have
diminished the additive benefit of ICPM. Because clinical practice
outside the setting of a clinical trial is often subject to greater
variation, it is possible that continuous invasive ICPM may provide
additional value in the absence of the stringent monitoring
requirements and protocol-driven therapy of a clinical trial.
Our objective therefore was to study the impact of ICPM on
clinical outcomes—in-hospital mortality and 6-month functional
outcome—in a setting reflective of contemporary clinical practice
by querying a prospective severe TBI registry in a high-volume
referral trauma center.
Methods
Approval of the respective Institutional Review Boards was
obtained at both the University of Michigan (HUM00079298) and
the All India Institute of Medical Sciences (AIIMS; IEC/NP-275-
2013) for this study. The Jai Prakash Narayan Apex Trauma Center
( JPNATC) at AIIMS in New Delhi, is the apex referral center for
TBI in New Delhi as well as for much of the rest of the country. It
has 30 triage and 36 intensive care unit (ICU) beds, with 300–600
severe TBI admissions every year. This study was performed under
the auspices of the University of Michigan/AIIMS research
collaboration. All data collection and clinical care were performed
at AIIMS, whereas analysis was performed at both institutions. The
study period was June 2010–July 2012.
Inclusion criteria
1. Patients with severe TBI (GCS score £8)
2. Age >12 years. The age cutoff of 12 years was selected as
being the threshold above which the clinical management of
TBI and ICP was more consistent in the study setting, and
also to maintain consistency with the selection criteria of the
BEST TRIP trial.
3. BTF criteria for invasive ICPM met:
a. Abnormal CT scan or
b. Normal CT scan plus any two of the following
i. Age >40
ii. Systolic blood pressure <90
iii. Unilateral or bilateral posturing
Exclusion criteria
Death within 24 hours.
Data source
The data source was the AIIMS/JPNATC Severe TBI Registry,
with prospective real-time electronic data capture supplemented by
manual data entry and review. Manual data entry and review were
performed by trained clinical research nurses with subsequent pe-
riodic review and validation by a physician. Six-month functional
status as estimated by the Glasgow Outcome Scale (GOS), when
available, is routinely entered into the registry.13 The 6-month GOS
score was obtained through telephone interview conducted by
trained research nurses and coordinators. A structured question-
naire was used during the interview with subsequent estimation of
the GOS score from the responses obtained.
Outcomes of interest
The primary outcome of interest was in-hospital mortality,
defined as death occurring from any cause during the patient’s
inpatient stay. This was selected as the primary outcome measure as
being an objective measure available for all patients. The secondary
outcome of interest was 6-month functional outcome in survivors
of the in-hospital stay, with poor functional outcome defined as a
GOS score of 3 or lower (including death following discharge from
the in-hospital stay). An additional rationale for the use of the 6-
month telephonic assessment of GOS as a secondary, rather than
primary, outcome measure was concern for a potential bias toward
patients with better outcome being more accessible to follow-up.
Supplemental analyses were then performed for the outcome
measures of 6-month mortality (including in-hospital deaths and
death following discharge) and functional outcome in 6-month sur-
vivors. Poor functional outcome in this analysis was therefore a GOS
score of 2 or 3, in patients who were alive at 6-month follow-up.
Intervention of interest and covariates
The intervention of interest was the use of invasive ICPM during
the patient’s ICU admission. All patients included in this study met
BTF criteria for ICPM; however, ICP monitors were placed variably
at the discretion of the admitting neurosurgeon, as is standard
practice at JPNATC. Intraparenchymal monitors (Codman,
Depuy Synthes, West Chester, PA) were exclusively used for
ICPM, with external ventricular drains (EVDs) reserved for the
management of hydrocephalus. This practice, similar to the protocol
of the BEST TRIP trial, reflects the perceived high rate of EVD
infection in the study setting.12 Co-variates in the analysis were
factors likely to influence the decision to place an ICP monitor, and
included demographics, admission GCS score, pupillary reactivity,
admission blood pressure, presence of extra-cerebral traumatic in-
jury (separated into acute spinal cord injury and other system in-
jury), and specific abnormalities on CT scan. Of note, many of these
variables are also known predictors of outcome following TBI and
therefore potential confounders.14 The specific abnormalities on
CT, entered into the model as separate variables, were: presence
of basal cisternal effacement, midline shift in millimeters, presence
of traumatic subarachnoid hemorrhage (tSAH), presence of epidural
hematoma (EDH), presence of subdural hematoma (SDH), and
presence of intraparenchymal contusion. Decompressive cra-
niectomy (DC) was performed at the discretion of the attending
neurosurgeon either pre-emptively, when, in the judgment of the
neurosurgeon the patient was at high risk for the development of
intracranial hypertension based on review of clinical and radio-
graphical data, or as a rescue measure for intracranial hypertension
refractory to medical management. Early DC (eDC) was defined in
our study as DC performed pre-emptively within 48 h of injury on
the basis of assessment of the patient’s clinical examination and
radiographical features (primarily midline shift and basal cisternal
effacement) and a consequent determination of a high risk for re-
fractory intracranial hypertension by the attending neurosurgeon.
Patients undergoing eDC subsequently underwent invasive ICP
monitor placement at the discretion of the attending neurosurgeon.
Additional analyses were performed to account for a potential
confounding effect of eDC on outcomes, because patients who
underwent eDC may have been less likely to undergo subsequent
ICPM and the interpretation and response to ICP values following
eDC may differ compared with patients with a ‘‘closed skull.’’ First,
a separate propensity score analysis was performed with inclusion
of eDC as a covariate in the calculation of the propensity score.
Second, a subgroup analysis was performed for the same outcome
measures, excluding all patients who underwent eDC.
Management principles
Although no standardized TBI protocol was used, the following
broad principles of management were in effect. Patients with severe
TBI were admitted to the neurointensive care unit (neuroICU) of
JPNATC. Care of patients with TBI in the neuroICU was provided
by neurosurgical housestaff supervised by senior neurosurgical
faculty and neurointensivists. Patients with GCS score £8 were
intubated, with tracheostomy performed when the need for airway
protection or mechanical ventilation was anticipated for >3 weeks.
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Normal saline was used to maintain euvolemia. Additionally, va-
sopressors were utilized as required to maintain cerebral perfusion
pressure (CPP) >60 mm Hg in patients with ICP monitors and mean
arterial pressure (MAP) >80–90 mm Hg in patients without ICP
monitors. When ICPM was used, the goal ICP was <20 mm Hg.
When an ICP monitor was not placed, the use of measures directed
at management of cerebral edema and raised ICP was based on
review of the patient’s neurological condition and serial CT im-
aging, without a standardized clinical management protocol.
Mannitol was used for osmotherapy with scheduled (rather than as-
needed) dosing regardless of whether ICPM was used, with doses
held for hypotension, hypovolemia, renal failure, serum sodium
>155 or serum osmolality >320. Partial pressure of carbon dioxide
(PCO2) was generally maintained between 30 and 40 mm Hg with
therapeutic hyperventilation to PCO2 <30 mm Hg used only for
limited duration as a rescue measure in the setting of cerebral
herniation or severe neurological deterioration caused by raised
ICP. Standard measures to maintain normothermia (temperature
<38C), including scheduled acetaminophen, evaporative surface
cooling with water spray and bedside fan, ice packs, and cooling
blankets, were utilized; however, hypothermia was not used. DC
was performed as described in the section above.
Statistical analysis
Overview of the propensity-score based analysis. Multiple
analyses were carried out to evaluate the effect of ICPM on each of
the outcomes: death and poor functional outcome at 6 months. For
each analysis, the main idea was to subset the patients such that the
probability of treatment was approximately equal within each
subgroup; in which case treatment can be viewed as having been
(approximately) randomized. Treatment-and-subgroup-specific
fractions of patients experiencing the outcome (e.g., death) were
calculated then combined. Propensity score analysis is useful in
estimating the effect of an intervention (ICPM) in a retrospective
observational study while adjusting for the covariates, or baseline
variables, that predict receiving the intervention.15,16 Propensity
score analysis decreases the bias due to confounding variables that
can occur when the intervention effect is estimated by simply
comparing outcomes among patients receiving the intervention
with those who did not.
Estimation of propensity score. Logistic regression model-
ing was first used to predict the probability of receiving ICPM for
each patient (i.e., the propensity score) as a function of several
potential confounding variables: age, gender, time from injury to
admission, admission GCS score, pupillary reactivity, admission
blood pressure, presence of associated spinal injury, presence of
associated non-neurological traumatic injury, presence of basal cis-
ternal effacement, midline shift in millimeters, presence of tSAH,
presence of SDH, presence of EDH, presence of non-evacuated
hematoma, and presence of parenchymal contusion.14 In addition,
performance of eDC was included as a covariate in the analysis of the
impact of ICPM as a potential confounder, as described earlier. A C-
index was calculated to evaluate the ability of the logistic regression
model to differentiate between patients pairs of patients discordant
with respect to use of ICPM. A C-index of >0.7 was considered
adequate, for use of the model to predict ICPM use.
Propensity-score adjusted comparison of ICPM versus
no-ICPM. The predicted probabilities (propensity scores) were
then recoded into deciles, and a new factor was computed indicating
the decile to which each patient was assigned based on their pro-
pensity score. The treatment-specific probability of dying was then
estimated within each decile as the fraction of subjects who died.
These decile-specific fractions were then averaged for each treat-
ment and compared. The null hypothesis of equal death probability
across treatments (i.e., ICPM versus no-ICPM) was then tested using
the Z-test based on the standard normal distribution. The procedure
outlined in the preceding paragraph was then repeated for the out-
come poor-functional status (GOS score £3). The primary analysis of
functional outcome included only patients with a 6-month mea-
surement available, and excluded patients who died in the hospital.
The response variate in this case should be interpreted as pertaining
to the probability of poor functional outcomes among surviving
patients (i.e., those discharged alive). Supplemental analyses were
then performed for the outcome measures of 6-month mortality
(including in-hospital deaths and deaths following discharge) and
functional outcome in 6-month survivors. Poor functional outcome
in this analysis was therefore a GOS score of 2 or 3, in patients who
were alive at 6-month follow-up.
All statistical analyses were carried out using SAS version 9.3
(SAS Institute; Cary, NC).
Results
There were 1530 admissions for severe TBI during the period of
the study. Of these, 1345 met criteria for inclusion in the study. The
median age was 32 years (interquartile range [IQR] 25–45 years),
89% of whom were male. The primary cause of injury was road
traffic accident (71%) with falls (20%) being the next common
cause. The distribution of variables and outcomes in patients with
and without use of ICPM is shown in Table 1.
Use of ICPM and decompressive craniectomy
and outcomes
Overall, 497 (37%) patients underwent ICPM. Median ICP at time
of monitor placement was 12 mm Hg (IQR 8–18 mm Hg). The
highest recorded ICP was >20 mm Hg in 75 of 497 (15%) patients. A
total of 589 (44%) patients underwent DC, whereas 491 (37%) un-
derwent eDC. In-hospital mortality was 35% (471/1345). Six-month
outcome assessment was available in 52% (454/874) of survivors. Of
these, 35% (161/454) were considered to have a poor functional
outcome (GOS score 1, 2, or 3). The GOS breakup among patients
with follow-up was: GOS 1= 92 (20%), GOS 2= 18 (4%), GOS
3= 55 (12%), GOS 4= 92 (20%), and GOS 5= 197 (43%).
Propensity score analysis
The C-index for the logistic regression model used to predict
ICPM was 0.74. For the propensity score analysis to evaluate
ICPM in the primary analysis, the deciles used to group patients by
propensity score were computed twice: once for the analysis of in-
hospital death, and a second time for the analysis of 6-month out-
comes (with the latter being restricted to patients who survived 6
months and had a 6-month outcomes measure available). Results
are summarized in Table 2A. ICPM was associated with a signifi-
cant ( p = 0.001) decrease in the probability of in-hospital death
of approximately 9%. ICPM did not have a significant effect ( p=
0.46) on the probability of poor function at 6 months. Including
early DC in the calculation of the propensity score, results were
virtually unchanged (Table 2B). In the subgroup analysis with
exclusion of patients who underwent eDC (n= 854), ICPM was
again associated with a 9% reduction in in-hospital mortality
( p= 0.002), whereas the difference in 6-month functional outcome
did not attain the threshold for statistical significance ( p= 0.08).
Results of the supplemental propensity score analysis with the
outcome measures of 6-month mortality and poor functional out-
come in 6-month survivors (GOS score= 2 or 3 in patients alive at 6
months) are depicted in Table 3. Use of ICPM was associated with a
significant 6% reduction ( p= 0.03) in 6-month mortality and no
INTRACRANIAL PRESSURE MONITORING AND OUTCOMES 855
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significant difference in poor functional outcome in 6-month sur-
vivors ( p= 0.17). In the subgroup analysis with exclusion of pa-
tients who underwent eDC (Table 3B, n= 854), ICPM was again
associated with a 7% reduction in 6-month mortality ( p= 0.03),
whereas the difference in poor functional outcome in 6-month
survivors did not attain the threshold for statistical significance
( p = 0.08).
Discussion
Our study examined the impact of invasive ICPM on outcomes
following severe TBI using a propensity score based analysis. The
use of ICPM was associated with a significant reduction in in-
hospital mortality (and 6-month mortality) with no significant dif-
ference in 6-month functional outcomes, whether defined as a GOS
score of 1–3 at 6 months in survivors of the in-hospital stay or a GOS
score of 2–3 in 6-month survivors. Strengths of our study include a
relatively large sample size (n= 1345), availability of 6-month
functional outcomes, availability for comparative analysis of a rel-
atively large group of control patients who did not undergo ICPM
despite meeting BTF criteria (because ICPM was not considered
standard of care in the study setting), validated prospective data entry
into the TBI registry, and a study population comparable to that of
the BEST TRIP trial. Our findings are consistent with those of studies
of the impact of ICPM from New York State and Los Angeles, both
of which revealed an association with lower in-hospital mortality,
but did not study 6-month functional outcomes.10,17 Similar to our
study, these studies examined existing practice outside the context of
a clinical trial, albeit in a different practice setting. The significant
reduction in mortality seen in our study, as well as the aforemen-
tioned studies, may therefore suggest that the continued use of ICPM
in appropriately selected patients is warranted.
The only large randomized controlled trial of invasive ICPM, the
BEST TRIP trial, did not, however, demonstrate an improvement in
outcomes with the use of invasive ICPM, although it must be noted
that the ICPM group in the BEST TRIP trial did have a lower 14-
day mortality (21% vs. 30%), a difference that did not reach sta-
tistical significance ( p= 0.18).12 The BEST TRIP trial, a clinical
trial with likely robust internal validity, has been subject to debate
with regards to the external validity of its findings.18,19 Potentially
the most important difference may be between the controlled mi-
lieu of a clinical trial, particularly one such as BEST TRIP with a
high degree of reported adherence to the study protocol, and routine
clinical practice, where the intensity and consistency of clinical
neurological monitoring as well as management may be subject to
greater variation. This may be particularly true at large teaching
institutions where a substantial proportion of care is provided by
clinicians in training, in understaffed clinical environments and
settings in which the bedside nurse in the ICU may not routinely
care for a large volume of neurosurgical patients. Clinical signs of
deterioration and impending herniation, such as a downward drift in
the GCS score or mild pupillary asymmetry, may therefore be
overlooked, whereas a numerical value such as the ICP, when
clearly above a target threshold, may trigger a more expeditious
response. Other important differences exist between our study and
the BEST TRIP trial. Barbiturate coma and hypertonic saline were
not used in our study setting, whereas both were used in the BEST
TRIP trial with a statistically significant difference in utilization
between the treatment and control arms.12 Where ICPM is not used,
it is likely essential to adhere to a rigorous protocol of frequent
clinical and imaging re-assessment and proactive management,
similar to the one used in BEST TRIP.
Similar to BEST TRIP, the use of ICPM was not associated with
an improvement in six-month functional outcome in our study.
This, however, does not necessarily imply more lives saved at the
cost of severe disability and an increased burden to society. This is
because in-hospital mortality was the more reliable and robust
outcome measure in our study, available for all patients, whereas
Table 1. Distribution of Variables in Patients with and without Use of ICPM
Variable
ICPM not used ICPM used
P valueN = 848 N = 497
Age in years, median (IQR) 32 (25–45) 31 (25–42) 0.22
Female gender 92 (11%) 59 (12%) 0.63
Hours from injury to admission, median (IQR) 3.46 (11.3) 3.08 (10.9) 0.26
Admission GCS, median (IQR) 6 (4–7) 7 (6–7) <0.0001
Pupillary reactivity absent <0.0001
One side 89 (10%) 44 (9%)
Both sides 183 (22%) 36 (7%)
Admission systolic blood pressure in mm Hg, median (IQR) 125 (112–140) 124 (112–136) 0.74
Admission PO2 in mm Hg, median (IQR) 185 (131–242) 200 (142–251) 0.014
Associated spine injury present 51 (6%) 32 (6%) 0.84
Other systemic trauma present 212 (25%) 128 (26%) 0.81
CT midline shift in mm (IQR) 2.9 (0–8) 0 (0–3) <0.0001
Basal cisternal effacement on CT 166 (20%) 61 (12%) 0.0007
Traumatic subarachnoid hemorrhage present 301 (35%) 202 (41%) 0.068
Extradural hematoma present 189 (22%) 54 (11%) <0.0001
Subdural hematoma present 433 (51%) 192 (39%) <0.0001
Intraparenchymal contusion present 498 (59%) 347 (70%) 0.0001
Non-evacuated hematoma present 127 (15%) 114 (23%) 0.0002
Early decompressive craniectomy performed 374 (44%) 117 (23%) <0.0001
In-hospital death 353 (42%) 118 (24%) <0.0001
Poor 6-month outcome 94 (11%) 66 (13%) 0.98
CT, computed tomography; GCS, Glasgow Coma Scale; ICPM, intracranial pressure monitoring; IQR, interquartile range; PO2, partial pressure of
oxygen.
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six-month outcome was available in about half of survivors. As
described earlier, we cannot exclude a potential bias toward pa-
tients with better functional outcomes being more accessible to
follow-up, thereby confounding the analysis of the impact of the
intervention on outcomes. A biological basis to the absence of an
impact of ICPM on functional outcomes despite a difference in
mortality certainly remains a possibility, because averting death
related to intracranial hypertension may not alter the substantial
underlying neurological injury and subsequent poor functional
outcome. It is also possible that the limited availability of high-
quality rehabilitation services in the post-discharge study setting
(again, similar to BEST TRIP) blunted any benefit in functional
outcome among survivors—that is, although the extent of sec-
ondary cerebral injury may have been minimized with the inter-
vention, patients were unable to translate this benefit into greater
independence, in the absence of appropriate physical, occupational,
speech/language, and other focused rehabilitative therapy. For all
these reasons, no definitive conclusion can be drawn from our study
regarding the impact of ICPM on functional outcomes.
The relatively high usage (37%) of eDC in our study partly
reflects the desire to minimize the subsequent need for ICP-directed
resources, and, especially, ICU length of stay. In fact, the perfor-
mance of DC in the DECRA trial was associated with a much lower
need for ICP-directed medical treatment and fewer ICU days.20 The
relatively low incidence of intracranial hypertension (15%) among
patients undergoing ICPM in our study may reflect the aggressive
use of eDC. The aggressive use of eDC may therefore dilute the
need for and subsequent impact of ICPM on outcomes. Conversely,
because the use of DC was associated with worse functional out-
comes in the DECRA trial, the aggressive use of eDC may con-
found functional outcomes. It is unlikely that eDC was a significant
confounder, however, because additional analyses with inclusion of
eDC as a co-variate in the calculation of the propensity score, as
well as subgroup analysis excluding all patients who underwent
eDC, yielded similar results.
The major limitation of our study is its retrospective nature,
although data were collected prospectively. The propensity score
analysis is likely to have mitigated any major imbalances in
baseline variables, however. Although the management of patients
with ICPM was largely guided by BTF guidelines and the princi-
ples outlined in the ‘‘Management principles’’ section above, there
was no mandatory standardized protocol in effect, as was employed
Table 2. Results of Propensity Score Analysis:
Impact of ICPM on In-Hospital Mortality
and 6-Month Functional Outcome in Survivors
of the In-Hospital Stay
Group
Propensity-score
adjusted
probability of
in-hospital death
Propensity-score
adjusted
probability of poor
function at 6 months
2A. Impact of ICPM on in-hospital death and 6-month
functional outcome. All patients included.
ICPM 0.247 0.361
No ICPM 0.320 0.323
Difference: ICPM
minus no-ICPM
-0.0732 0.0387
SE (difference) 0.0248 0.0529
Z-score: difference/SE -2.949 0.732
P value P= 0.003 P= 0.464
2B. Impact of ICPM on in-hospital death and 6-month
functional outcome with eDC included as covariate
for propensity score. All patients included.
ICPM 0.253 0.357
No ICPM 0.317 0.323
Difference: ICPM
minus no-ICPM
-0.0638 0.0348
SE (difference) 0.0251 0.0525
Z-score: difference/SE -2.544 0.663
P value P= 0.011 P= 0.507
2C. Impact of ICPM on in-hospital death and 6-month
functional outcome: subgroup excluding patients who
underwent eDC
ICPM 0.182 0.310
No ICPM 0.270 0.223
Difference: ICPM
minus no-ICPM
-0.0879 0.0866
SE (difference) 0.0282 0.0492
Z-score: difference/SE -3.119 1.758
P value P= 0.002 P= 0.079
Poor 6-month functional outcome in this analysis was defined as GOS
score £3 (including patients who died following discharge from the
hospital).
eDC, early decompressive craniectomy; ICPM, intracranial pressure
monitoring; SE, standard error.
Table 3. Results of Propensity Score Analysis:
Impact of ICPM on 6-Month Mortality (Dead at
6 Months, Including Death during In-Hospital
Stay and Deaths following Discharge) and 6-Month
Functional Outcome in Patients Alive at 6 Months
Group
Propensity-score
adjusted probability
of death within
6 months
Propensity-score
adjusted probability
of poor function
at 6 months among
6-month survivors
3A. Impact of ICPM on 6-month death and functional
outcome among 6-month survivors. All patients included.
ICPM 0.381 0.213
No ICPM 0.373 0.147
Difference: ICPM
minus no-ICPM
-0.0554 0.0659
SE (difference) 0.0262 0.0478
Z-score: difference/SE -2.118 1.379
P value P= 0.034 P = 0.168
3B. Impact of ICPM on 6-month mortality and functional
outcome among 6-month survivors: subgroup excluding
patients who underwent eDC
ICPM 0.243 0.179
No ICPM 0.309 0.105
Difference: ICPM
minus no-ICPM
-0.0659 0.0741
SE (difference) 0.0303 0.0417
Z-score: difference/SE -2.179 1.777
P value P= 0.029 P = 0.076
Poor 6-month functional outcome in this analysis was defined as a GOS
score of 2 or 3 in patients alive at 6 months.
eDC, early decompressive craniectomy; ICPM, intracranial pressure
monitoring; SE, standard error.
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in the BEST TRIP trial; our study was, instead, a pragmatic
evaluation of existing clinical practice. Six-month outcome was
available for only about half of survivors and as previously men-
tioned a bias toward patients with better outcomes being more
likely to respond to telephone outreach is possible. The aggressive
use of eDC may have mitigated any potential benefit from the use of
ICPM to direct therapy. We were unable to analyze potential dis-
parities in resource utilization and costs between the intervention
and comparator groups. Finally, despite our inclusion of major
co-variates proven to predict poor outcome following TBI in the
logistic regression model used to calculate the propensity score, the
influence of unmeasured confounders cannot be entirely excluded.
In conclusion, the use of invasive ICPM in patients with severe
TBI was associated with decreased in-hospital mortality. Con-
tinued utilization of ICPM in appropriately selected patients, as
well as further clinical trials in settings where the use of invasive
ICPM is not the standard of care, may therefore be warranted.
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